Breast Implant Update: Scrutiny Continues
Executive Summary
At an FDA General and Plastic Surgery Devices panel held in August to make recommendations on postmarketing issues related to silicone gel breast implants, the agency said it will continue to monitor patient safety via the postapproval studies and surgeon adverse reports and has asked that groups work together to improve follow-up and registry enrollment.
You may also be interested in...
The Future of the Stem Cell Market
The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.